A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Obstructive Sleep Apnea
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 主要终点
- Apnea Hypopnea Index measured by Respiratory Inductance Plethysmography (RIP)
研究概览
简要总结
The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.
详细描述
Insomnia is characterized by difficulties initiating and maintaining sleep, or complaints of non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.
Ramelteon is under global development by Takeda Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.
This study is being conducted to assess the safety of Ramelteon in subjects with obstructive sleep apnea. Participation this this study is anticipated to be about 1.5 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Known hypersensitivity to ramelteon or related compounds, including melatonin.
- •Known hypersensitivity to Ventolin® or related compounds.
- •Previously participated in a study involving ramelteon.
- •Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to Day 1 of study medication, whichever is longer.
- •Clinical history of acute or chronic respiratory failure, severe chronic obstructive pulmonary disease, or hypercapnia (Partial Pressure of Oxygen in Arterial Blood greater than or equal to45 mmHg).
- •History of or currently has right ventricular hypertrophy on electrocardiogram or right heart failure.
- •Periodic leg movement with arousal index (per hour of sleep) greater than 20 as seen at polysomnography screening.
- •Apnea hypopnea index greater than 15 as seen at polysomnography screening.
- •Acute clinically significant illness within 2 weeks or has been hospitalized within 4 weeks of study participation.
- •Sleep schedule changes required by employment within three months prior to Day 1 of study medication, or has flown across greater than three time zones within seven days prior to screening.
- •Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to Day 1 of study medications.
- •History of seizures, sleep apnea, restless leg syndrome, period limb movement disorder, other known sleep disorders, schizophrenia, bipolar disease, mental retardation, or cognitive disorder.
- •History of psychiatric disorder within the past 12 months.
- •History of drug addiction or drug abuse within the past 12 months.
- •History of alcohol abuse within the past 12 months and/or regularly consumes 4 or more alcoholic drinks per day.
- •Unable to discontinue the use of hypnotics for the duration of the study.
- •Any clinically important abnormal finding, other than chronic obstructive pulmonary disease, as determined by medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
- •Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to Day 1 of study medication.
- •Hematocrit value greater than 55% at screening.
- •Positive hepatitis panel.
- •Any additional condition(s) that in the Investigator's opinion would:
- •affect sleep-wake function
- •prohibit the subject from completing the study
- •not be in the best interest of the subject
- •Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:
- •Anxiolytics
- •Hypnotics
- •Antidepressants
- •Anticonvulsants
- •Sedating H1 antihistamines
- •Systemic steroids
- •Decongestants
- •Over-the-counter and prescription stimulants
- •Over-the-counter and prescription diet aids
- •Central nervous system active drugs and narcotic analgesics
- •Lipophilic beta blockers
- •Melatonin
- •St. John's Wort
- •Kava-kava
- •Gingko biloba
研究组 & 干预措施
Ramelteon 16 mg QD or Placebo QD
干预措施: Ramelteon or Placebo (Drug)
结局指标
主要结局
Apnea Hypopnea Index measured by Respiratory Inductance Plethysmography (RIP)
时间窗: Periods 1 and 2.
Central Apnea Index.
时间窗: Periods 1 and 2.
Mean Oxygen Saturation for the entire night.
时间窗: Periods 1 and 2.
Obstructive Apnea Index.
时间窗: Periods 1 and 2.
Hypopnea Index.
时间窗: Periods 1 and 2.
次要结局
- Mean Oxygen Saturation for the entire night.(Periods 1 and 2.)
- Oxygen Saturation Means for Awake Sleep Stage.(Periods 1 and 2.)
- Oxygen Saturation Means for Non-Rapid Eye Movement Sleep Stage.(Periods 1 and 2.)
- Oxygen Saturation Means for Rapid Eye Movement Sleep Stage.(Periods 1 and 2.)
- Percentage of oxygen saturation is less than 80%.(Periods 1 and 2.)
- Latency to Persistent Sleep.(Periods 1 and 2.)
- Total Sleep Time.(Periods 1 and 2.)
- Sleep Efficiency.(Periods 1 and 2.)
- Awake Time after Persistent Sleep.(Periods 1 and 2.)
- Number of Awakenings after Persistent Sleep.(Periods 1 and 2.)
- Subjective Sleep Latency.(Crossover Period 1 AM; Crossover Period 2 AM)
- Subjective Total Sleep Time.(Periods 1 and 2.)
- Subjective Sleep Quality.(Periods 1 and 2.)
- Subjective Number of Awakenings.(Periods 1 and 2.)
- Subjective Ease of Falling Back to Sleep after Awakening.(Periods 1 and 2.)
- Subjective Level of Alertness.(Periods 1 and 2.)
- Subjective Ability to Concentrate.(Periods 1 and 2.)
- Percentage of Total Sleep Time in REM sleep(Periods 1 and 2.)
- Percentage of Total Sleep Time in Stage 1 NREM sleep(Periods 1 and 2.)
- Percentage of Total Sleep Time in Stage 2 NREM sleep(Periods 1 and 2.)
- Percentage of Total Sleep Time in Stage 3/4 NREM sleep(Periods 1 and 2.)
- Percentage of Total Sleep Time in latency to REM as determined by polysomnography(Periods 1 and 2.)